Owens & Minor, Inc. — 2014 Form 10-K
Filing identity: The request metadata names ACCENDRA HEALTH INC, but the supplied filing is for Owens & Minor, Inc. This summary reflects the filing. It covers the fiscal year ended December 31, 2014; quarterly figures are identified separately where relevant.
Business context and reporting period
Owens & Minor is a healthcare logistics company distributing medical and surgical supplies and providing packaging and logistics services to healthcare providers and manufacturers. It reports Domestic and International segments. During 2014 it acquired Medical Action Industries and Ireland-based ArcRoyal, expanding surgical-kit and procedure-tray capabilities. Their combined consideration was $261.6 million, net of cash acquired and including $13.4 million of assumed capital-lease obligations; the acquisitions had no material effect on 2014 operating results.
Financial results and position
| Metric | 2014 | 2013 | Change / note |
|---|---|---|---|
| Net revenue | $9.440 billion | $9.072 billion | Up 4.1% |
| Gross margin | $1.170 billion; 12.39% | $1.117 billion; 12.31% | Margin up 8 basis points |
| Operating earnings (GAAP) | $159.5 million; 1.69% of revenue | $198.1 million; 2.18% | Down 19.5% |
| Net income | $66.5 million | $110.9 million | Down 40.0% |
| Diluted EPS | $1.06 | $1.76 | Adjusted EPS was $1.76 vs. $1.90 (non-GAAP) |
| Cash from operating activities | $(3.8) million | $140.6 million | Working-capital outflow |
| Capital expenditures | $70.8 million | $60.1 million | Higher investment |
| Cash and cash equivalents | $56.8 million | $101.9 million | Down $45.1 million |
| Total debt | $613.8 million | $216.2 million | Increase largely reflects new notes |
| Total assets | $2.735 billion | $2.324 billion | — |
SG&A rose 7.3% to $927.0 million, or 9.82% of revenue versus 9.52%. Interest expense increased 38.7% to $18.2 million. The effective tax rate rose to 47.4% from 40.1%. Year-end DSO was 22.1 days in both years; inventory turnover declined to 10.1 from 10.4.
Domestic revenue increased 3.0% to $8.952 billion; International revenue rose 27.3% to $488.3 million, or 5.2% of consolidated revenue. Domestic segment operating earnings declined to $209.3 million from $211.9 million. International operating loss widened to $6.7 million from $1.4 million.
Fourth-quarter 2014 revenue was $2.492 billion versus $2.319 billion in fourth-quarter 2013; quarterly net income was $14.0 million versus $27.9 million. 2014 GAAP results included $42.8 million of acquisition-related and exit/realignment charges, a $14.9 million debt-retirement loss, a $3.9 million estimated claim-settlement loss, and a $3.7 million net gain from purchase-accounting fair-value adjustments. Management’s non-GAAP adjusted measures exclude specified items and are not substitutes for GAAP results.
Material changes, financing, outlook, and risks
- Operating cash flow turned negative as working capital absorbed cash, driven mainly by vendor-payment timing and higher working-capital needs associated with sales growth. Inventory increased 13.1% to $872.5 million, while accounts payable declined 5.5% to $608.8 million.
- The company issued $275 million of 3.875% senior notes due 2021 and $275 million of 4.375% notes due 2024, and redeemed its $200 million 6.35% notes due 2016, paying a $17.4 million redemption premium. Its revolving-credit capacity increased to $450 million and was extended to 2019. At year-end, $33.7 million was drawn and approximately $411 million remained available; the company reported covenant compliance.
- Management said available cash, operating cash generation, and revolving-credit borrowing were expected to be sufficient for working capital, investment, debt and lease payments, dividends, and other needs. This is management’s assessment, not a quantified earnings or revenue forecast. The board approved a 1% increase in the quarterly dividend to $0.2525 per share in February 2015.
- The company expected approximately $9.5 million of additional 2015 exit and realignment charges for activities already initiated. It also identified pricing pressure, customer and supplier concentration, GPO and customer contract retention, acquisition integration, healthcare-market changes, regulatory compliance, product liability, cyber/system disruption, foreign-exchange exposure, and customer credit failures as risks.
- Sales to members of Novation, MedAssets, and Premier represented approximately 82% of 2014 consolidated revenue. Products from the ten largest domestic suppliers accounted for approximately 57%; Covidien and Johnson & Johnson supplied approximately 14% and 10%, respectively.
- The company reported ordinary-course legal matters and judged pending matters not likely to have a material adverse effect. It accrued $3.9 million for a proposed UK customer-claim settlement; related receivables were approximately $11.5 million at year-end. The filing reports effective controls overall, but acquired businesses representing $340 million of assets and $46.9 million of 2014 revenue were excluded from the 2014 internal-control assessment; management planned to include them in 2015.
Most important facts to verify
- Confirm the issuer identity: the supplied 10-K is Owens & Minor, not ACCENDRA HEALTH INC.
- Reconcile the substantial decline in GAAP earnings with the listed charges and assess the assumptions behind management’s adjusted, non-GAAP results.
- Review the causes and sustainability of negative operating cash flow, working-capital growth, and inventory turnover deterioration.
- Assess post-acquisition integration, International segment losses, and the expected 2015 realignment costs.
- Review debt maturities, credit-facility covenants, interest costs, and the capacity to sustain dividends and other cash uses.
- Track the UK settlement and receivable recovery, and the planned 2015 internal-control assessment of Medical Action and ArcRoyal.